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CLINICAL ARTICLE
J Neurosurg Spine 33:392–397, 2020
Spinal myxopapillary ependymomas (MPEs) repre-sent a clinically and biologically distinct subset of ependymomas, which are WHO grade I and tend 
to occur in the conus medullaris, cauda equina, and/or 
filum terminale. These tumors are rare, with a reported 
incidence of 1 per million person-years, and have a slight 
predominance in males and Caucasians.1 The natural his-
tory of spinal MPE is long, with reported 10-year overall 
and progression-free survival rates of 92% and 61%, re-
spectively.2
ABBREVIATIONS GTR = gross-total resection; MDACC = MD Anderson Cancer Center; MPE = myxopapillary ependymoma; RFS = relapse-free survival; RT = radio-
therapy; STR = subtotal resection.
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OBJECTIVE The authors sought to describe the long-term recurrence patterns, prognostic factors, and effect of adju-
vant or salvage radiotherapy (RT) on treatment outcomes for patients with spinal myxopapillary ependymoma (MPE).
METHODS The authors reviewed a tertiary institution IRB-approved database and collected data regarding patient, 
tumor, and treatment characteristics for all patients treated consecutively from 1974 to 2015 for histologically confirmed 
spinal MPE. Key outcomes included relapse-free survival (RFS), postrecurrence RFS, failure patterns, and influence of 
timing of RT on recurrence patterns. Cox proportional hazards regression and Kaplan-Meier analyses were utilized.
RESULTS Of the 59 patients included in the study, the median age at initial surgery was 34 years (range 12–74 years), 
30 patients (51%) were female, and the most common presenting symptom was pain (n = 52, 88%). Extent of resection 
at diagnosis was gross-total resection (GTR) in 39 patients (66%), subtotal resection (STR) in 15 (25%), and unknown in 
5 patients (9%). After surgery, 10 patients (17%) underwent adjuvant RT (5/39 GTR [13%] and 5/15 STR [33%] patients). 
Median follow-up was 6.2 years (range 0.1–35.3 years). Overall, 20 patients (34%) experienced recurrence (local, n = 
15; distant, n = 5). The median RFS was 11.2 years (95% CI 77 to not reached), and the 5- and 10-year RFS rates were 
72.3% (95% CI 59.4–86.3) and 54.0% (95% CI, 36.4–71.6), respectively.
STR was associated with a higher risk of recurrence (HR 6.45, 95% CI 2.15–19.23, p < 0.001) than GTR, and the median 
RFS after GTR was 17.2 years versus 5.5 years after STR. Adjuvant RT was not associated with improved RFS, regard-
less of whether it was delivered after GTR or STR. Of the 20 patients with recurrence, 12 (60%) underwent salvage treat-
ment with surgery alone (GTR, n = 6), 4 (20%) with RT alone, and 4 (20%) with surgery and RT. Compared to salvage 
surgery alone, salvage RT, with or without surgery, was associated with a significantly longer postrecurrence RFS (me-
dian 9.5 years vs 1.6 years; log-rank, p = 0.006).
CONCLUSIONS At initial diagnosis of spinal MPE, GTR is key to long-term RFS, with no benefit to immediate adjuvant 
RT observed in this series. RT at the time of recurrence, however, is associated with a significantly longer time to second 
disease recurrence. Surveillance imaging of the entire neuraxis remains crucial, as distant failure is not uncommon in 
this patient population.
https://thejns.org/doi/abs/10.3171/2020.2.SPINE191534
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Owing to the rarity of spinal MPEs, the optimal man-
agement remains unclear. Retrospective studies suggest 
that gross-total resection (GTR) is the most important 
factor in achieving long-term disease control.2–4 The role 
of adjuvant radiotherapy (RT) is less clear, with some 
studies suggesting benefit to upfront combined modality 
treatment regardless of the extent of resection.2,3,5–7 The 
objective of the current study was to assess the long-term 
clinical outcomes of consecutive patients managed at our 
institution, as well as to analyze recurrence patterns, prog-
nostic factors, and the effect of adjuvant or salvage RT.
Methods
We queried an IRB-approved database at our tertiary 
institution for all patients with histologically confirmed 
spinal MPE treated consecutively between 1974 and 2015. 
Patient characteristics, tumor location and details, and 
treatment course at initial diagnosis and relapse, as well 
as all disease outcomes, were abstracted from the shared 
medical record.
All resections were piecemeal, owing to the difficulty 
in removing MPE in an en bloc fashion and the institu-
tional practice at the time. Extent of resection was defined 
as either GTR or subtotal resection (STR), based on sur-
geon assessment rather than postoperative imaging due 
to the difficulty in distinguishing residual disease from 
postoperative changes. RT was delivered following pri-
mary resection or at disease recurrence, at the discretion 
of the treating physicians. RT was delivered via an exter-
nal beam approach, using various techniques, such as 2D 
anterior-posterior fields, 3D conformal RT, and intensity-
modulated RT, based on era of treatment and physician 
discretion.
The primary endpoint was relapse-free survival (RFS), 
calculated from the date of initial surgery to either the 
date of imaging confirmation of recurrence or the date of 
last clinical follow-up for patients who did not experience 
recurrence of their disease. The secondary endpoint was 
postrecurrence RFS, which was calculated from the date 
of initial recurrence to the date of subsequent recurrence 
or the date of last clinical follow-up for patients who did 
not experience a second recurrence.
Statistical Analysis
Cox proportional hazards regression was used to iden-
tify clinical factors associated with RFS on univariate 
analysis, as well as multivariable analysis when appropri-
ate. The Kaplan-Meier method was used to estimate sur-
vival, and the log-rank test was used to compare survival 
curves. Statistical analysis was performed using SAS v9.4 
(SAS Institute), and p values < 0.05 were considered sta-
tistically significant.
Results
The patient characteristics of the 59 patients who met 
inclusion criteria for this study are summarized in Table 
1. The median age at initial surgery was 34 years (range 
12–74 years), and 30 patients (51%) were female. The most 
common symptoms at initial presentation were pain in 
52 patients (88%), numbness in 15 (25%), weakness in 10 
(17%), and abnormal gait in 9 patients (15%). A majority of 
patients underwent MRI for diagnosis (43 patients, 85%) 
and the remainder had a combination of myelograms along 
with other diagnostic imaging, with 2 patients (3.4%) as-
sessed with CT only. Two-thirds of patients (n = 39, 66%) 
in this series were diagnosed with disease in the lumbo-
sacral region, and the remainder of patients (n = 20, 34%) 
had disease in the thoracic spine.
Extent of resection at diagnosis was GTR in 39 (66%), 
STR in 15 (25%), and unknown in 5 (9%) patients. After 
the initial surgery, 10 patients (17%) underwent adjuvant 
RT (5 patients after GTR and 5 patients after STR) to a 
median dose of 49 Gy (range 45–58 Gy) delivered via con-
ventional fractionation. Of these 10 patients, 7 had disease 
in the lumbosacral region and 3 had disease in the thoracic 
region. At last follow-up, 9 patients (15%) had experienced 
a single recurrence, 7 (12%) had 2 recurrences, 2 patients 
(34%) had 3 recurrences, and 2 patients (34%) had 4 recur-
rences.
TABLE 1. Patient and treatment characteristics
Characteristic No. (%)
Age, yrs
 ≤35 33 (56)
 >35 26 (44)
Karnofsky Performance Scale score
 ≥70 53 (90)
 <70 6 (10)
Sex
 Female 30 (51)
 Male 29 (49)
Symptoms at presentation
 Pain 52 (88)
 Numbness 15 (25)
 Weakness 10 (17)
 Abnormal gait 9 (15)
 Urinary incontinence 6 (10)
 Bowel incontinence 5 (8)
 Tingling 2 (3)
Extent of resection at initial surgery
 GTR 39 (66)
 STR or biopsy 15 (25)
 Not documented 5 (9)
Adjuvant RT after initial surgery
 No 49 (83)
 Yes 10 (17)
Any recurrence after initial surgery
 No 39 (66)
 Yes 20 (33)
Salvage treatment for initial recurrence
 RT alone 4 (20)
 RT and surgery 4 (20)
 Surgery alone 12 (60)
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Median follow-up from time of initial surgery was 6.2 
years (range 0.1–35.3 years). Overall, 20 patients (34%) ex-
perienced disease recurrence (local, n = 15; distant, n = 5). 
Among all patients, the median RFS was 11.2 years (95% 
CI 7.7 to not reached), and the 5- and 10-year RFS rates 
were 72.8% (95% CI 59.4–86.3) and 54.0% (95% CI 36.4–
71.6), respectively (Fig. 1). The median survival time from 
initial surgery was 6.6 years (range 0.1–35.3 years), and at 
the time of this analysis 54 patients (92%) were alive and 
continued to be followed.
On univariate analysis (Table 2), STR was associated 
with a higher risk of disease recurrence (HR 6.45, 95% CI 
2.15–19.23, p < 0.001) compared to GTR. The 5-year RFS 
after GTR was 81.6% (95% CI 66.6–96.7) versus 50.7% 
(95% CI 21.9–79.6) after STR (log-rank, p < 0.001; Fig. 2). 
Among all patients, adjuvant RT was not associated with 
improved RFS (log-rank, p = 0.97; Fig. 3). When analyzed 
separately by the type of resection, adjuvant RT was not 
associated with improved RFS after either GTR (log-rank, 
p = 0.92) or STR (log-rank, p = 0.27). Age ≤ 35 years, 
disease location within the spine (i.e., thoracic vs lumbo-
sacral), and adjuvant RT dose ≥ 50 Gy were not associated 
with RFS (p > 0.05 for each).
Overall, 20 patients (34%) had a recurrence: 15 pa-
tients (75% of this subgroup) had a local recurrence and 
5 patients (25% of this subgroup) had a distant recurrence 
(recurrence at a different spinal segment). At the time of 
recurrence, 12 patients (60%) subsequently underwent sal-
vage treatment with surgery alone (GTR, n = 6), 4 (20%) 
with RT alone, and 4 patients (20%) with both surgery and 
RT. Compared to salvage surgery alone, salvage RT with 
or without surgery was associated with a significantly lon-
ger postrecurrence RFS (median 9.5 years vs 1.6 years; 
log-rank, p = 0.006; Fig. 4 upper). The 5-year postrecur-
rence RFS was 27.5% (95% CI 1.1–54.0) versus 84.6% 
(95% CI 56.9–100) for patients treated with surgery alone 
versus RT, with or without surgery, respectively. We sepa-
rately analyzed the subset of patients who were treated 
with surgery alone at first diagnosis but who received RT 
(with or without surgery) at the time of disease relapse (n 
= 8). For these patients, there was a trend to improvement 
in time to next recurrence in the salvage setting exceeding 
the disease-free interval observed from initial diagnosis 
(median 9.5 vs 2.9 years; log-rank, p = 0.061; Fig. 4 lower). 
Of the patients who received salvage RT (with or without 
surgery), none had received prior RT. No other clear se-
lection bias for the choice of salvage treatment was noted 
with regard to initial extent of resection, recurrence loca-
tion (distant vs local), extent of resection at recurrence, 
RFS, or age at recurrence (Supplemental Tables 1 and 2).
Of the 5 patients with initial distal recurrence, 2 had re-
TABLE 2. Univariate analysis for RFS
Factor p Value HR (95% CI)
Age, yrs (>35 vs ≤35) 0.49 1.37 (0.56–3.40)
STR vs GTR (n = 54) <0.001 6.45 (2.15–19.23)
T spine vs LS spine 0.66 1.24 (0.48–3.21)
Adjuvant RT (no vs yes) 0.97 1.02 (0.34–3.09)
Dose (<50 vs ≥50 Gy, n = 10) 0.15 0.17 (0.01–1.92)
LS = lumbosacral; T = thoracic.
FIG. 1. RFS of all patients.
FIG. 2. RFS stratified by extent of resection. Figure is available in color 
online only.
FIG. 3. RFS stratified by treatment with adjuvant RT. Figure is available 
in color online only.
Unauthenticated | Downloaded 09/07/21 04:08 PM UTC
J Neurosurg Spine Volume 33 • September 2020 395
Kotecha et al.
ceived initial adjuvant RT (GTR, n = 1; STR, n = 1), while 
the other 3 had received initial surgery alone (GTR, n = 
2; STR, n = 1). Distal failure was located in the inferior-
adjacent cord in 2 patients, inferior-nonadjacent cord in 
1, superior-adjacent cord in 0, and superior-nonadjacent 
cord in 2 patients. Of the 15 patients with an initial local 
recurrence, 2 had received adjuvant RT while the remain-
der received initial surgery alone. Two of these patients 
went on to a subsequent distant recurrence: 1 patient in 
the superior-nonadjacent cord and 1 patient in the brain 
(nonadjacent).
Discussion
Management of spinal MPE represents a unique clini-
cal challenge owing to the difficulty in achieving a com-
plete en bloc resection, disease- and treatment-related 
morbidity associated with anatomical location, risk of lo-
coregional and distant recurrence, rarity of this disease, 
and the relatively young age at disease presentation. Given 
the paucity of data in the literature with significant hetero-
geneity among analyses, additional data are sorely needed. 
Our present study of spinal MPE identified several key 
findings which supplement our understanding of this rare 
disease. First, initial GTR offers the best chance of cure, 
and has better outcomes than upfront combined modality 
therapy. Second, adjuvant RT after initial surgery is not 
associated with improved RFS. However, RT salvage ther-
apy is associated with significant and dramatic improve-
ments and prevention of a second disease relapse. Lastly, 
given the long-term follow-up in this series, we demon-
strated that up to one-fourth of patients suffer treatment 
failure elsewhere in the spine, a finding that highlights the 
potential for late neuraxis failure in these patients.
Resection is the primary management strategy for 
spinal MPE, and GTR is associated with significantly 
improved disease outcomes.2,4,8 The frequency of GTR 
varies between 27% and 100% in the literature, and the 
data presented in our study demonstrate a clear benefit in 
terms of RFS with aggressive upfront GTR.8 Of course, 
in general, no surgeon undertakes a deliberate STR when 
a GTR is feasible, and therefore, even a definitive conclu-
sion regarding GTR versus STR is difficult to promulgate 
in such a retrospective series. In our initial analysis of 37 
patients with spinal MPE published in 2011, GTR demon-
strated a numerically improved median RFS of 11.2 years 
compared to 5.5 years with STR, results which did not 
meet statistical significance (log-rank, p = 0.075).9 How-
ever, in the present study with updated analysis, additional 
patients, and longer follow-up, GTR was associated with 
a statistically significant improvement in median RFS of 
17.2 years compared to 5.5 years with STR. These data 
are consistent with the largest series of spinal MPE pa-
tients, performed using pooled data from MD Anderson 
Cancer Center (MDACC) and the Rare Cancer Network, 
which demonstrated in multivariable analysis that STR 
was associated with adverse local control (LC; HR 2.08, 
95% CI 1.13–3.82, p = 0.01) and progression-free survival 
(HR 2.14, 95% CI 1.38–4.24, p = 0.02).2 An older study 
similarly demonstrated that GTR was associated with im-
proved overall survival (OS; median 19 years with GTR 
vs 14 years with STR).4 Furthermore, a large review of the 
literature with aggregated data from 1602 patients demon-
strated a strong association with GTR and improved OS at 
5 and 10 years.8 Together, these data collectively highlight 
the importance of obtaining a radical complete resection 
of spinal MPE and support the role of multidisciplinary 
management and specialized surgical expertise among 
newly diagnosed patients.
The role of adjuvant RT following initial resection is 
controversial, as this has never been prospectively evaluat-
ed in a randomized controlled manner, and consequently, 
the literature contains predominantly single-institutional 
retrospective series. All of these series span very long 
eras, and therefore the imaging, surgical, and radiothera-
peutic techniques are extremely heterogeneous. Although 
reports in the literature have generally demonstrated im-
proved outcomes with the use of immediate adjuvant RT, 
none of the retrospective series utilize predefined criteria 
for selecting adjuvant RT, thereby introducing enormous 
bias and making data interpretation even more complicat-
ed.2,3,5–7 An initial report from MDACC described the out-
comes of 51 patients with spinal MPE and demonstrated 
that adjuvant RT significantly improved local control (LC) 
after STR (10-year LC was 0% after STR alone vs 65% 
with adjuvant RT, p = 0.008), as well as following GTR 
(median LC was 4.75 years after GTR alone vs 10.5 years 
FIG. 4. Upper: RFS after salvage stratified by treatment with RT. 
Lower: RFS for patients treated with surgery alone and who received 
RT at the time of relapse; the same patients are plotted on both survival 
curves. Figure is available in color online only.
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with adjuvant RT, p = 0.03). These data were subsequent-
ly combined in a larger pooled analysis of 183 patients 
with spinal MPE by Weber and colleagues,2 in which 47% 
of patients received adjuvant RT. In their multivariable 
analysis, after accounting for age, extent of resection, and 
metastasis at diagnosis, treatment with surgery and adju-
vant RT was associated with both improved LC (standard-
dose RT: HR 0.34, 95% CI 0.15–0.77; high-dose RT: HR 
0.34, 95% CI 0.16–0.71; p < 0.001) and progression-free 
survival (standard-dose RT: HR 0.28, 95% CI 0.12–0.60; 
high-dose RT: HR 0.28, 95% CI 0.14–0.57; p < 0.001). 
Ten-year progression-free survival was 70% with adju-
vant RT compared to < 40% with surgery alone, but no 
differences were specifically reported regarding extent of 
resection and effect of RT.2 In contrast, we found no sig-
nificant benefit in RFS with adjuvant RT in both the ini-
tial and present analysis, regardless of extent of resection.9 
Although both studies had similar follow-up periods and 
roughly the same proportion of patients achieving GTR 
(54%–66%), key differences in selection criteria for adju-
vant RT in both centers may lead to significant selection 
bias. For example, of the 10 patients treated with adjuvant 
RT in this series, 5 had a GTR, whereas one-third of STR 
patients (the remaining 5 patients) received adjuvant RT. 
Therefore, our series could have limited power for demon-
strating the benefit given that half of the patients who re-
ceived adjuvant treatment received it after GTR and there-
fore were in the group least likely to benefit from RT. This 
hypothesis was bolstered by the finding that after enrich-
ing the group with patients treated with adjuvant RT at re-
currence, the benefit of RT was more easily demonstrated. 
Therefore, high-risk groups (STR or questionable GTR) 
should still be evaluated and considered for postopera-
tive RT given the risk of disease recurrence and potential 
benefits of adjuvant treatment. It is important to note that 
pediatric patients were not well represented in this series, 
and as other series demonstrate a higher risk of recurrence 
in the pediatric population, even in the setting of GTR, our 
results should not be extrapolated to pediatric patients.10
A unique finding from our series is that at first recur-
rence, treatment with RT improves median RFS by almost 
8 years, from 1.6 years with surgery alone to 9.5 years with 
the addition of RT. Thus, our data suggest that for patients 
who do not receive RT in the adjuvant setting, salvage RT 
is crucial in reducing the risk of further recurrence, even 
after salvage GTR. Although we were unable to report 
toxicity data, Weber and colleagues demonstrated a trend 
toward increased late adverse events with surgery plus RT 
compared with surgery alone (43.9% vs 56.1%, respective-
ly; p = 0.07).2 However, in light of recent advances in RT 
techniques that minimize the dose to surrounding critical 
structures and associated toxicity, such as proton therapy, 
the therapeutic ratio may shift to favor upfront adjuvant 
therapy as opposed to salvage treatment.11–15 Molecular 
characterization of these tumors is key to shedding some 
light as to whether there are distinct molecular entities 
which are likely to recur, as patients in this series experi-
enced up to 4 episodes of disease relapse, despite similar 
initial pathologies.
Distant spinal failure as a component of disease recur-
rence is relatively common. In our series, 25% of failures 
were distant. No obvious trend emerged regarding the lo-
cation of distant failures as they were found to be located 
either adjacent, nonadjacent, cranial, or caudal to the site 
of initial disease. In the study by Weber and colleagues, 
29% had distant spine failure and 19% had brain failure.2 
A recent series of 19 patients reported that 58% of patients 
had distant disease, 36% of which was present at diag-
nosis.16 Weber et al. further note that given the indolent 
clinical course of asymptomatic distant disease, close ob-
servation is a reasonable strategy. Given the high rates of 
distant failure, surveillance imaging of the entire neuraxis 
is a crucial component of disease management.
Study Limitations
It is important to note the limitations of the current 
analysis, including its retrospective nature and small sam-
ple size. Because the study spanned 4 decades, advances 
in imaging (CT to MRI), surgery, and RT (3D conformal 
to intensity-modulated RT) occurred. Management was 
subject to selection bias and follow-up schedules were 
inconsistent. Treatment outcomes outside of recurrence-
specific data, such as recovery from surgery or presence 
or absence of neurological deficits at the time of initial 
surgery or at disease relapse, would be useful to include 
given the comparison across modalities (surgery with or 
without RT); however, these variables were not studied in 
this analysis. Additionally, we were unable to report toxic-
ity data. Despite these limitations, our data represent an 
important contribution to the literature for this rare entity, 
given the long-term follow-up and meticulous assessment 
of initial surgery and recurrence patterns, which cannot 
easily be performed in larger database studies.
Conclusions
Owing to the relatively young age at presentation and 
long natural history of spinal MPE, our findings support 
aggressive initial surgical resection to provide the longest 
recurrence-free interval and highlight the benefit of RT at 
the time of salvage for those patients treated with surgery 
alone in the upfront setting. Surveillance imaging of the 
entire neuraxis is crucial as distant failure is not uncom-
mon.
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